Prerpints.org logo
Preprint
Review

This version is not peer-reviewed.

Adult Male Hypogonadism: A Laboratory Medicine Perspective on its Diagnosis and Management

A peer-reviewed article of this preprint also exists.

Submitted:

17 August 2023

Posted:

22 August 2023

You are already at the latest version

Abstract
Testosterone (T), the principal androgen secreted by the testes, plays an essential role in male health. Male hypogonadism is diagnosed based on a combination of associated clinical signs and symptoms and laboratory confirmation of low circulating T levels. In this review we have highlighted factors, both biological and analytical, that introduce variation into the measurement of serum T concentrations in men; these need to be considered when requesting T levels and interpreting results. There is an ongoing need for analytical standardisation of T assays and harmonisation of pre- and post-analytical laboratory practices, particularly in relation to the laboratory reference intervals provided to clinicians. Further, there is a need to share with service users the most up-to-date and evidence-based action thresholds for serum T as recommended in the literature. Estimation of free testosterone may be helpful. Causes of secondary hypogonadism should be considered. A comprehensive approach is required in the management of male hypogonadism, including lifestyle modification, as well as medication where appropriate. The goal of treatment is resolution of symptoms as well as optimisation of metabolic, cardiovascular and bone health. The advice of an endocrinologist should be sought, where there is doubt about the cause and appropriate management of the hypogonadism.
Keywords: 
male hypogonadism
;  
androgen deficiency
;  
testosterone
;  
assay
;  
erectile dysfunction
Subject: 
Medicine and Pharmacology  -   Endocrinology and Metabolism

1. Introduction

Testosterone (T), the principal androgen secreted by the testes, plays an essential role in male health [1]. It is important for the development and maintenance of adult male secondary sexual characteristics. Male hypogonadism is diagnosed based on a combination of associated clinical signs and symptoms (Table 1), and laboratory confirmation of low circulating T levels and decreased fertility [1, 2]; further testing is then required to elucidate the underlying aetiology. It has a prevalence estimated at 6-12% in the general population, increasing with age [3], but may be found in up to 40% of men with type 2 diabetes mellitus (T2D) (with overt and borderline hypogonadism at 17% and 25%, respectively) [4,5,6]. In older males, there is an overlap between the non-specific effects of ageing and late-onset hypogonadism [7]. Longitudinal studies have demonstrated both hypogonadism and erectile dysfunction (ED) to be independently associated with increased total and cardiovascular disease (CVD)-related mortality, thus highlighting the importance clinically of this diagnosis [8,9,10].
The British Society for Sexual Medicine (BSSM) and the European Association of Urology (EAU) guidelines on sexual dysfunction recommend that all men with ED should have, as a minimum standard, an initial measurement of T, and, in those with a poor response to phosphodiesterase type 5 inhibitors (PDE5i), T should be rechecked [2, 5]. In men with T2D, NICE guidance [11] recommends an annual check/assessment for ED due to its prevalence in this group of >70%; accordingly, this should identify hypogonadism in up to 40% of patients. The BSSM, the Society for Endocrinology (SfE), the American Urological Association (AUA) and the American Association of Clinical Endocrinologists (AACE) [5, 12–14], and other national and international guidelines, recommend screening of T levels men with T2D, obesity (waist circumference >102 cm or BMI >30 kg/m2) and metabolic syndrome, which will lead to increased detection of candidates for testosterone replacement therapy (TRT). Clinicians across diverse medical specialties (e.g., diabetes, endocrinology, urology, sexual medicine, general practice) are increasingly checking T levels driven in relation to a growing understanding of the risks associated with male hypogonadism. Prevailing clinical guidance on the diagnosis and management of hypogonadism in men should be supported by the clinical laboratory with accurate and precise analytical methodologies for the measurement of T levels, and other appropriate hormones and proteins, as this will have a direct impact on treatment decisions for patients (for example, the initiation and monitoring of TRT).

2. Causes of Male Hypogonadism

Primary hypogonadism is caused by testicular failure and is characterised by low serum T and high luteinizing hormone (LH) and follicle stimulating hormone (FSH) concentrations in the blood. For this reason, primary hypogonadism is also known as hypergonadotropic hypogonadism. In secondary hypogonadism (hypogonadotropic hypogonadism), defects in the hypothalamus or pituitary result in low T levels because of insufficient stimulation of the Leydig cells in the testes. It is also associated with low or low-normal FSH and LH levels. Patients with secondary hypogonadism can have their fertility restored by hormonal stimulation, whereas those with primary hypogonadism resulting from testicular failure cannot. Low T concentrations can be caused by a combination of both primary and secondary hypogonadism (also called mixed hypogonadism) that reflects defects in the hypothalamus and/or the pituitary as well as the testes [15].
Causes of primary hypogonadism include Klinefelter’s syndrome, undescended testes, mumps orchitis, haemochromatosis, cancer chemotherapy and normal ageing (Table 2). Causes of secondary hypogonadism include Kallman syndrome, pituitary disorders including pituitary adenoma, human immunodeficiency virus (HIV), obesity, head injury and stress-related hypogonadism [15] (Table 2).

3. Factors affecting the measurement of total testosterone levels

3.1. Biological variation of T levels

T circulates in both protein-bound and non-protein-bound (free) forms. In men, ~50% is loosely bound to albumin, 44% bound to sex hormone binding globulin (SHBG), 4% is bound to other proteins (e.g., cortisol-binding protein) and 2% is free (non-protein bound) [16]. Serum total T levels, like many hormones, can be influenced by various biological factors (Table 3), which contribute to fluctuations in T levels within individuals (which vary significantly). It is important to be aware of these variables, which can be broadly classified into either physiological or analytical factors, to avoid misdiagnosing hypogonadism. The physiological factors within a male that play an important role are summarised in Table 3 [16, 17].

3.2. Analytical Variation

3.2.1. Total Testosterone Assays

Serum total T assays clearly play an important role in the clinical evaluation of male hypogonadism. In UK clinical biochemistry laboratories, total T levels in adult males are routinely measured using non-radioactive methods on automated analysers, often by commercial immunoassays (>80% [18], also termed ‘direct-assays’), but sometimes by mass spectrometry (MS); however, significant inter-assay variation was observed between different immunoassays and different MS platforms in a UK-wide survey of NHS clinical laboratories, with intra-assay variability being another technical constraint [18]. The direct-assays are so-called because there is no extraction of T from any binding protein included in the method procedure, which uses antibodies to directly bind T for subsequent quantitation in the sample. This lack of extraction can leave the method more prone to interference (e.g., from other similar cross-reacting molecules) and, at lower T levels, aberrations in the levels of serum binding proteins can lead to measurement inaccuracies. Liquid chromatography-tandem MS (LC-MS/MS) is considered a better method due to potentially higher specificity and sensitivity; however, from reports in the United Kingdom National External Quality Assurance Scheme (UK NEQAS) for Steroid Hormones, some of the mass spectrometry assays are actually being outperformed by the better immunoassays. UK NEQAS data from 2021 shows between-laboratory imprecision of 5-10% for all T assays (covering a concentration range = 0.5–35 nmol/L); there is also a range of biases between the different methods, which is an issue when trying to apply universal reference ranges or cut-off thresholds in the diagnosis and management of hypogonadism. Consequently, wide variability has been reported in the reference ranges provided by UK laboratories, both between the laboratories and different methods used, and even amongst users of the same method, with the lower limit of normal (LLN) ranging from 4.9–11 nmol/L [18].
Varying LLN and upper limits of normal (ULN) have potential consequences for men with all types of hypogonadism in terms of initiation or not of TRT, and adjustment to therapy (e.g., lowering the dose), respectively. Moreover, the quality of the data used to calculate these normative ranges for the commercial immunoassays is questionable, both in terms of controlling the pre-analytical factors described above in sampling protocols (as far as practically possible), and the applicability of the derived intervals to the population sampled; this degrades the clinical value in their use for diagnosing hypogonadism.

3.2.2. Sex hormone binding globulin (SHBG) assays and calculated free testosterone (cFT)

Like T levels, SHBG is measured using immunoassay in the UK, and these assays are prone to similar analytical variability and differing manufacturer biases, leading to inconsistent results between the methods. Interestingly, SHBG has now been shown to be associated with symptoms of hypogonadism and mortality [19]. According to the free hormone hypothesis, only unbound T is bioactive and thus able to bind to androgen receptors in the target tissues [20]. The estimation of calculated free testosterone (cFT) is considered useful in patients with conditions that alter SHBG levels, and where the total T levels is close to the LLN (see Table 4), to avoid the under/over-diagnosis of hypogonadism. Variations equations have been used to derive cFT, most commonly the Vermeulen equation in the UK [18]. It is worth noting that the equation is only an estimation of free testosterone and incorporates the test results of albumin, SHBG and total testosterone in the calculation (combining variability for three tests). Equilibrium dialysis followed by MS is considered the reference method for estimating FT [21]. This method is not available in the UK for routine clinical practice and other direct measurement methods tend to be inaccurate and are not recommended.

4. Laboratory Evaluation/Diagnosis of Male Hypogonadism

Diagnosis of hypogonadism in men is based upon the identification of its non-specific features through clinical assessment and blood testing. Serum total T is the most widely accepted biomarker to establish biochemically the presence of hypogonadism. When requesting serum T levels in men, the following categories are useful reasons for testing: 1) diagnosis of primary hypogonadism; 2) diagnosis of secondary hypogonadism: pituitary/hypothalamic disease; 3) late onset hypogonadism (also known as testosterone deficiency, adult-onset hypogonadism, and functional hypogonadism); and 4) for improving patient fertility [1].
As there is a circadian variation (diurnal rhythm) in the secretion of T, with peak levels in the early morning, specimens taken to measure total T should be taken in the morning between 7.00 AM and 11:00 AM, which is especially important in men aged <40 years [22]. This diurnal variation, however, is substantially blunted in older men, and in men with lower T levels [23], but it may still be evident (even in elderly subjects), supporting the morning blood test recommendation in all age groups [24]. In night/shift workers, T should be measured within 3 hours of waking up, because the diurnal rhythm is primarily driven by sleeping patterns, and not endogenously by circadian factors. Laboratory confirmation of hypogonadism in male shift workers is complicated and warrants specialist referral.
Evaluation of hypogonadism should not be made during acute illnesses. T levels are influenced by insulin, with a 75 g glucose load shown to lower T by 25% [24]. Fasting T levels were reported to be up to 30% higher in healthy subjects compared to those taken in a non-fasting state [24, 25]. As such, the EAU guidelines [2] now recommend that T is measured in a fasting state, although the evidence base for this is still inadequate and this does create practical difficulties for routine blood tests, which have generally moved to using non-fasting samples (e.g., checks for diabetes and dyslipidemia). However, Livingston et al. [26], found no significant effect of fasting in a real-world UK clinical laboratory study of samples of 213 patients with suspected hypogonadism. Until further evidence to support this is available, the recent BSSM guideline [5] supports measuring T in the fasting state for an initial test, but suggests a pragmatic approach is taken by clinicians since most patients do not routinely go around in a fasting state; consequently, insistence on fasting samples may introduce a barrier to patient investigation and a non-fasting early morning sample is considered acceptable.
When circulating T levels are borderline or low on first measurement, the test should be repeated on at least two occasions (ideally after a period of four weeks) as T is released in a pulsatile manner and the result of a single assay may be misleading), and also to check serum SHBG and albumin (required to estimate FT or bioavailable T levels, e.g. using the Vermeulen equation available at http://www.issam.ch/freetesto.htm). Where total T levels are between 8–12 nmol/L, the FT level should be checked [2, 5], and serum LH and FSH levels should also be measured. Measurement of LH, FSH and prolactin will help to differentiate secondary from primary hypogonadism [2]. This is not as clear cut in older men [27]. In the case of known or suspected abnormal SHBG levels, FT should also be estimated [5].
Serum prolactin levels are recommended when both LH and FSH levels are low. A very low total T (<5.2 nmol/L), and low LH and FSH are more likely to be associated with hyperprolactinaemia, pituitary tumour or other pituitary pathology. Regarding other investigations, in men with T levels <5.2 nmol/L and increased prolactin levels or reduced LH and FSH levels, pituitary magnetic resonance imaging (MRI) should be performed to exclude a pituitary adenoma/empty sella [22, 28]. Hyperprolactinaemia is associated with ED, loss of libido/sexual interest and anorgasmia, and should be ruled in/out by blood testing in all men with these findings. It is frequently accompanied by androgen deficiency because high prolactin levels suppress LH production and, consequently, cause hypogonadism. A moderate elevation of prolactin levels (<1000 mU/L) is unlikely to cause ED. There can be many causes for hyperprolactinaemia, both medical and physical, including stress, drugs (such as neuroleptics and anti-emetics), prolactin-secreting pituitary tumour (identification of these cases is very important), hypothyroidism and chronic renal failure. The presence of macroprolactin or ‘big–big’ prolactin, a heterogenous complex of prolactin and immunoglobulin A (150–170 kDa) which cross-reacts in the total prolactin assay, can lead to over-investigation of hyperprolactinaemia; this benign condition is the apparent cause of hyperprolactinaemia in about 20% of cases [29, 30]. The presence of macroprolactin should be considered in all cases of mild-to-moderate elevations in serum prolactin as it is measured in all commercial immunoassays, to a varying extent. Macroprolactinaemia is detected by re-assaying prolactin after precipitation with polyethylene glycol (PEG). Protocols to detect macroprolactin are in place in most clinical laboratories when prolactin levels are above a method-dependent cut-off (usually at levels of ~600–700 mU/L). Patients with persistent and unexplained hyperprolactinaemia should be referred to an endocrinologist.
At present, there is no definitive reference range or LLN threshold value for serum T that can be used to reliably and accurately identify men with hypogonadism; in part, this is because hypogonadal symptoms manifest at varying levels between individuals, and because of the variation in results between T immunoassays and their associated reference ranges. Thus, diagnostic and therapeutic T threshold concentrations represent a spectrum across the biological continuum and are dependent on the clinical context [31]. However, the following threshold values function as action cut-off values for clinical practice rather than reference ranges. Patients with suggestive clinical features and two consecutive morning levels <8 nmol/L are likely to have hypogonadism. Although there are no studies directly comparing different testosterone cut-off levels for intervention, total testosterone <8 nmol/L correlates well with sexual symptoms of male hypogonadism and there is strong evidence in this group for a high prevalence of complications of hypogonadism and symptomatic improvement with treatment. Most of the current guidelines also agree with this action limit and the premise that further assessment for the aetiology of hypogonadism is required in these men.
The non-specific symptoms found in hypogonadism and variation in what T levels are considered ‘normal’ make the diagnosis challenging clinically [33]. Guidelines agree that total T >12 nmol/L is unlikely to represent hypogonadism. One exception would be when the LH level is raised and there is a concern about subclinical/compensated primary hypogonadism, or androgen receptor cytosine, adenine, guanine (CAG) repeat polymorphism [34]. This latter point relates to the androgen receptor (AR) mediating the peripheral effects of testosterone. The main mechanism of action for the AR is to direct regulation of gene transcription. Exon 1 of the AR gene contains a polymorphic sequence of CAG repeats, which varies in number from 10 to 35, and which encodes polyglutamine stretches of the AR transactivation domain [34]. The evidence suggests that the number of CAG repeats in the coding region of the androgen receptor gene is negatively correlated with the transcriptional activity of the AR [35]; stanworth2011dyslipidaemia]. Recently it was reported that CAG repeat number may partially influence the risk of mortality in older men [36] and in men with T2D [37]. Thus, it may be that future evaluation of androgen status will include determining the CAG repeat number as well as total and free testosterone.
In a national survey of UK clinical biochemistry laboratories [18], the responses showed considerable variation in practice in the measurement and reporting of male T levels, including the laboratory reference ranges provided. Reference intervals based on population distributions are often misinterpreted as the ‘normal’ range and can lead to confusion in the absence of clear treatment guidelines [32], particularly as treatment ambiguity often arises when T levels are borderline and, unfortunately, a borderline range is not acknowledged by a majority of laboratories [18]. We would recommend that clinicians become familiar with the T assays utilised in their local laboratory and the associated reference intervals given, whilst also having an appreciation that reference ranges represent 95% of the normal population; these ranges may also have been derived by the commercial manufacturer of the T assay being used, and in a different patient population, with samples potentially not collected under standardised conditions. Reference ranges for total T are not designed to replace evidence-based action thresholds.
Improvements in the standardisation of T assays and the consistency of reporting between laboratories is required. If abnormal results are found and confirmed, discussion with, or referral to, a specialist endocrinology clinic should be considered. Many patients with hypogonadism can be treated in primary care, but where a pituitary or hypothalamic disorder is suspected, the advice of an endocrinologist should always be sought. Furthermore, the advice of an endocrinologist is necessary where there is doubt about the cause and appropriate management of the hypogonadism.

5. Therapeutic intervention and thresholds for monitoring TRT in male hypogonadism

A comprehensive approach is required in the management of male hypogonadism, including exercise and diet modification, as well as medication where appropriate. Testosterone treatment is only one potential option in the older man with low serum T in the context of holistic management where successful lifestyle measures (especially optimisation of body weight) and careful optimisation of comorbidities have important health benefits and may, by themselves be sufficient to normalise their serum T [31]. Weight loss and lifestyle change should always form part of the management, but a significant elevation in T is not usually seen unless more than 5%–10% of weight loss is achieved. TRT is also recommended in men with HIV and chronic renal disease. Screening for low T (Table 2) is recommended, especially in the presence of hypogonadal symptoms in all other populations (including those with CVD, chronic pulmonary diseases, cirrhosis, rheumatoid arthritis and cancer), because although such conditions are potentially associated with an increased prevalence of low T, there is a lack of evidence for benefit of TRT in asymptomatic individuals [22].
The goal of treatment is in the restoration of symptoms including a sense of well-being (energy levels and mood), libido and sexual function, prevention/improvement of already established osteoporosis and optimization of bone density, restoration of muscle strength and improvement in mental acuity and metabolic parameters [27]. Accurate and precise determination of T levels in men, taking into consideration the biological and analytical factors described earlier when taking samples and interpreting results, will directly impact decisions about the initiation of TRT. Significant benefits have already been shown in hypogonadal men following TRT [38] in the Testosterone Trial cohort, including improvement in sexual function, quality-of-life, vitality, physical performance, mood, depression, bone mineral density and anaemia. In males aged >40 years with a total T level of ≤8.7 nmol/L (≤250.7 ng/dL), TRT was found to improve symptoms and significantly reduce mortality in men with T2D [39]. Two further longitudinal studies confirmed this in men with low total T levels and T2DM/underlying elevated cardiovascular risk, although using different cut-off points (10.4 nmol/L (299.7 ng/dL) [40], and total T of 12 nmol/L (345.8 ng/dL) and cFT of 0.25 nmol/L (7.2 ng/dL) [5, 41, 42]. Improvement in sexual function, improved erection, and restored/enhanced PED5I responsiveness was also seen in those given TRT [42, 43]. Moreover, there is evidence of a decrease in insulin resistance by TRT in men with T2D and with chronic heart failure [44, 45].
In terms of the diagnostic and treatment thresholds for intervention in hypogonadal symptomatic men, the guidelines of the BSSM and International Society for Sexual Medicine (ISSM) both cite a total T level <12 nmol/L or cFT <225 pmol/L (<0.225 nmol/L) based on two separate morning (<11AM) samples as usually requires TRT [5]. Total T levels >12 nmol/L or FT of >225 pmol/L (>0.225 nmol/L) do not require T Therapy. Levels between 8–12 nmol/L may require a trial of TRT (for a minimum of 6 months, based on improvement in symptoms). Evidence also supports treatment of men with total T concentrations <14 nmol/L in symptomatic men with pre-diabetes, aiming to prevent progression to overt T2DM. In those with appropriate symptoms, cFT levels (<225 pmol/L, 0.225 nmol/L) provides supportive evidence for TRT, and they were found to closely relate to the clinical symptoms and all-cause mortality in the EMAS study [46]. Raised LH levels and T below normal, or in the lower quartile of the reference range, indicates inadequate testicular function prompting consideration of TRT dependent on the severity of symptoms [5]. For those started on TRT, typically there will be a perceived benefit after 3 months; however, if there is no impact on symptoms after 3-6 months, then the diagnosis needs to be re-evaluated, and discontinuation of TRT considered [5].
Men with total T <8.0 nmol/L (<230.5 ng/dL) or cFT <0.180 nmol/L (<5.2 ng/dL) usually require TRT, while those with total T between 8.0–12.0 nmol/L (230.5–345.8 ng/dL) may require TRT, depending on the presence of symptoms associated with hypogonadism. The timeline for improvement in symptoms following initiation of testosterone supplementation is variable, but generally shorter following prescription of testogel than depot testosterone (normally testosterone undecanoate). There is evidence of under prescribing of testosterone in primary care with marked variation between general practices in testosterone prescribing with an indication that the variation was largely related to general practitioner choice [47].
Quality of life (QoL) is a summation of psychological variables, which contribute to the subjective perception that life is worthwhile [48]. Positive effects of TRT on QoL have been seen in larger cohorts of hypogonadal men of up to more than 1.000 patients in uncontrolled ‘real-life’ settings or registries [49, 50]. Effects on muscle mass [51, 52] and bone mass take much longer to be manifest [53]. Specifically Snyder et al. [53] reported that 12-months of treatment with of 1% testosterone gel in men >65 years of age and serum T levels <9.5 nmol/L (275 ng/dL) resulted in a significant increase in volumetric bone mineral density. Lumbar spine bone mineral density (BMD) starts to increase after 6 months of treatment and may continue for 3 years of treatment [54].
It is recommended that there is monitoring of serum testosterone level 3-4 weeks after initiation of testogel supplementation and before the 4th injection of depot testosterone, aiming for a trough serum T level within the laboratory reference range, with titration of testosterone dose accordingly. Once established on a specific dose of testosterone replacement, monitoring is undertaken annually and will include a check of full blood count (FBC), focusing on haematocrit and haemoglobin level and prostate specific antigen (PSA).
Contraindications to TRT are locally advanced or metastatic breast and prostate carcinoma, elevated haematocrit >48%, severe chronic heart failure (New York Heart Association Stage IV) and untreated obstructive sleep apnoea [55]. All guidelines report that TRT is to be avoided in men who desire fertility in the next 6-12 months [56]. If there is uncertainty about the safety of testosterone replacement, referral to a specialist Endocrinology clinic is recommended.
A number of studies have focused on the cardiometabolic benefits of TRT in hypogonadal men in the context reports that low levels predict an increase in all-cause mortality during long-term follow-up [40]. In the TIMES 2 study [57], the efficacy of transdermal 2% testosterone gel was evaluated over 12 months in hypogonadal men with T2D and/or metabolic syndrome. TRT reduced insulin resistance in the overall population and in T2D individuals. Glycaemic control was significantly better in the testosterone treated group than the placebo group, with improvements also seen in total and LDL cholesterol, lipoprotein a (Lpa), body composition. In a subsequent study [58] TRT in the form of testosterone undecanoate was independently associated with reduced mortality in men with T2D. PDE5i use was associated with decreased mortality in all patients those not on testosterone replacement, suggesting independence of effect. Regarding diabetes prevention, in the T4DM study [59], men aged 50–74 years, with a waist circumference of 95 cm or higher, a serum T concentration of 14·0 nmol/L or lower but without and impaired glucose tolerance (oral glucose tolerance test [OGTT] 2-h glucose 7·8–11·0 mmol/L) or newly diagnosed T2D were randomised to receive an intramuscular injection of testosterone undecanoate (1000 mg) or placebo for 2 years. At 2 years, 2-hour glucose of 11·1 mmol/L or higher on OGTT was reported in 21% of 413 participants with available data in the placebo group and 12% of 443 participants in the testosterone group (relative risk 0·59, 95% CI 0·43 to 0·80). Thus, TRT for 2 years reduced the proportion of participants with T2D beyond the effects of a lifestyle programme.
Some concern has been expressed regarding the cardiovascular safety following testosterone replacement. Thus, while most studies demonstrate either benefit or no increase in cardiovascular events, a few have reported higher CVD events in men on TRT; specifically, the retrospective cohort study reported in 2013 by Vigen et al [60] and Finkle et al. [61] who examined 55,593 insurance claims and compared the incidence rate of myocardial infarction in the 12 months prior to, and 3 months after, the initial prescription of TRT, suggested that TRT was likely to increase cardiovascular (CV) risk. However in a definitive landmark multicentre study recently published [62], 5246 men 45 to 80 years of age who had pre-existing or a high risk of cardiovascular disease testosterone levels of less than 10.4 nmol/L (300 ng/dl) were randomly assigned to receive daily transdermal 1.62% testosterone gel. A primary cardiovascular end-point event occurred in 7.0% in the testosterone group and in 7.3% in the placebo group. Thus, there was no excess of cardiovascular events.

6. Conclusions

In this review, we have highlighted factors, both biological and analytical, that introduce variation into the measurement of serum total T levels in men; these need to be considered when requesting T levels and interpreting patient results. Inconsistencies have been reported between clinical laboratories and there is an ongoing need for analytical standardisation of T assays and harmonisation of pre- and post-analytical laboratory practices, particularly in relation to the laboratory reference intervals provided to clinicians. Further, there is a need to share with service users the most up-to-date and evidence-based action thresholds for T as recommended in the literature. A recent expert joint statement on testing and interpretative recommendations by the SfE and Association for Clinical Biochemistry and Laboratory Medicine (ACB) [33, 63] is a welcome attempt to address existing gaps between clinical and laboratory medicine associations, as well as national external quality assurance provider for clinical laboratories, to improve the current situation for patients requiring measurement of their T levels. Future work should consider how to develop harmonised T reference intervals/treatment thresholds for all UK clinical laboratories, leading to reduced variation and clinical confusion in the approach to diagnosis and treatment of male hypogonadism; ideally, this would be done by ensuring the total T results from the different methods and manufacturers are more closely aligned (akin to what was done with glycated haemoglobin A1c (HbA1c) standardisation), not any easy undertaking without the introduction of universal reference standards. Programmes such as that of the Centers for Disease Control and Prevention (CDC) reference laboratory for standardizing hormone measurements, including for total T ([[64]; https://www.cdc.gov/labstandards/pdf/hs/HoSt_Brochure.pdf], and the availability of reference materials will help to do this, but not whilst it remains voluntary. Other less robust approaches would be to 1) use assay-specific treatment thresholds or 2) to establish harmonised reference ranges/action thresholds for T, as described by Travison et al. [65], that can be applied across laboratories by cross-calibrating T assays to a reference method (such as LC-tandem Mass Spectrometry) and standard calibrator(s) in healthy non-obese male population. Pre- and post-analytical Harmonisation of laboratory function relating to measurement of T also need consideration to address the biological/sample collection aspects and the evidence-based advice provided by laboratories to clinicians.

7. Key Take Home Points in the interpretation of serum total testosterone levels (based on the recent SfE/ACB Joint Statement [33, 63])

  • Patients are likely to have hypogonadism if they have suggestive clinical findings, two consecutive (>2 weeks apart) morning (<11:00AM) ideally fasting levels of <8 nmol/L (albeit cross-reference with local assay bias). T levels >12 nmol/L makes a diagnosis of hypogonadism unlikely (including one level >12 nmol/L, even if other results are lower). Morning, fasting levels in the 8–12 nmol/L range may occur in eugonadal or hypogonadal subjects, and so require further clinical assessment/investigation.
  • T measurements during an acute illness, after 11 AM are not reliable to diagnose male hypogonadism. Note, laboratory method bias can affect T results, as may those with altered circadian rhythm (e.g. night workers).
  • Estimation of free testosterone ((http://www.issam.ch/freetesto.htm) is helpful in those with SHBG levels above and below the reference range as it may help identify or exclude hypogonadism even when testosterone levels are ‘normal’ or low, respectively.
  • A low T level measured in a morning sample (<11AM) requires a serum prolactin, LH and FSH measurement to rule out secondary hypogonadism and SHBG measurement (to aids in the interpretation of the T levels, including the estimation of free testosterone). These additional tests, if measured, help to inform decisions concerning management of potential hypogonadism.
  • The prescription and monitoring of TRT in hypogonadal men, in line with the prevailing clinical guidelines, is the responsibility of the clinicians caring for the patient. TRT where appropriately prescribed can be associated with great benefit in terms of both quality of life and longer-term health outcomes.

Author Contributions

The authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not Applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Livingston, M. , Kalansooriya, A. , Hartland, A.J., Ramachandran, S., et al., Serum testosterone levels in male hypogonadism: Why and when to check-a review. International Journal of Clinical Practice 2017, 71, e12995. [Google Scholar]
  2. Dohle, G. , Arver, S. , Bettocchi, C., Jones, T., et al., EAU guidelines on male hypogonadism. European Association of Urology 2016, 13, 33. [Google Scholar]
  3. Wu, F.C. , Tajar, A. , Beynon, J.M., Pye, S.R., et al., Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine 2010, 363, 123–135. [Google Scholar]
  4. Araujo, A.B. , Esche, G. R., Kupelian, V., O’Donnell, A.B., et al., Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology & Metabolism 2007, 92, 4241–4247. [Google Scholar]
  5. Hackett, G. , Kirby, M. , Rees, R.W., Jones, T.H., et al., The british society for sexual medicine guidelines on male adult testosterone deficiency, with statements for practice. The World Journal of Mens Health 2023, 41, 508. [Google Scholar]
  6. Anderson, S.G. , Heald, A. , Younger, N., Bujawansa, S., et al., Screening for hypogonadism in diabetes 2008/9: Results from the cheshire primary care cohort. Primary Care Diabetes 2012, 6, 143–148. [Google Scholar]
  7. Livingston, M. , Jones, R. , Hackett, G., Donnahey, G., et al., Screening for hypogonadism in primary healthcare: How to do this effectively. Experimental and Clinical Endocrinology & Diabetes 2018, 126, 176–181. [Google Scholar]
  8. Pye, S. , Huhtaniemi, I. , Finn, J., Lee, D., et al., Late-onset hypogonadism and mortality in aging men. The Journal of Clinical Endocrinology & Metabolism 2014, 99, 1357–1366. [Google Scholar]
  9. Dong, J.-Y. , Zhang, Y. -H., Qin, L.-Q., Erectile dysfunction and risk of cardiovascular disease: Meta-analysis of prospective cohort studies. Journal of the American College of Cardiology 2011, 58, 1378–1385. [Google Scholar]
  10. Malipatil, N.S. , Yadegarfar, G. , Lunt, M., Keevil, B., et al., Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes. Endocrinology, Diabetes & Metabolism 2019, 2, e00064. [Google Scholar]
  11. Health, N.I. for, Excellence, C., NG28: Type 2 diabetes in adults: management. 2015.
  12. Seftel, A.D. , Kathrins, M., Niederberger, C., Critical update of the 2010 endocrine society clinical practice guidelines for male hypogonadism: A systematic analysis, in: Mayo Clinic Proceedings, Elsevier, 2015, pp. 1104–1115.
  13. Handelsman, Y. , Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., et al., American association of clinical endocrinologists and american college of endocrinology–clinical practice guidelines for developing a diabetes mellitus comprehensive care plan–2015—executive summary. Endocrine Practice 2015, 21, 413–437. [Google Scholar]
  14. Mulhall, J.P. , Trost, L. W., Brannigan, R.E., Kurtz, E.G., et al., Evaluation and management of testosterone deficiency: AUA guideline. The Journal of Urology 2018, 200, 423–432. [Google Scholar]
  15. Dandona, P. , Rosenberg, M. T., A practical guide to male hypogonadism in the primary care setting. International Journal of Clinical Practice 2010, 64, 682–696. [Google Scholar]
  16. Diver, M. , Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Annals of Clinical Biochemistry 2006, 43, 3–12. [Google Scholar] [CrossRef]
  17. Trost, L.W. , Mulhall, J. P., Challenges in testosterone measurement, data interpretation, and methodological appraisal of interventional trials. The Journal of Sexual Medicine 2016, 13, 1029–1046. [Google Scholar]
  18. Livingston, M., Downie, P., Hackett, G., Marrington, R., et al., An audit of the measurement and reporting of male testosterone levels in UK clinical biochemistry laboratories. International Journal of Clinical Practice 2020, 74.
  19. Ramachandran, S. , Strange, R. C., Fryer, A.A., Saad, F., et al., The association of sex hormone-binding globulin with mortality is mediated by age and testosterone in men with type 2 diabetes. Andrology 2018, 6, 846–853. [Google Scholar]
  20. Keevil, B.G. , Adaway, J. , Assessment of free testosterone concentration. The Journal of Steroid Biochemistry and Molecular Biology 2019, 190, 207–211. [Google Scholar] [CrossRef]
  21. Vermeulen, A. , Verdonck, L. , Kaufman, J.M., A critical evaluation of simple methods for the estimation of free testosterone in serum. The Journal of Clinical Endocrinology & Metabolism 1999, 84, 3666–3672. [Google Scholar]
  22. Khera, M. , Adaikan, G. , Buvat, J., Carrier, S., et al., Diagnosis and treatment of testosterone deficiency: Recommendations from the fourth international consultation for sexual medicine (ICSM 2015). The Journal of Sexual Medicine 2016, 13, 1787–1804. [Google Scholar]
  23. Brambilla, D.J. , Matsumoto, A. M., Araujo, A.B., McKinlay, J.B., The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. The Journal of Clinical Endocrinology & Metabolism 2009, 94, 907–913. [Google Scholar]
  24. Caronia, L.M. , Dwyer, A. A., Hayden, D., Amati, F., et al., Abrupt decrease in serum testosterone levels after an oral glucose load in men: Implications for screening for hypogonadism. Clinical Endocrinology 2013, 78, 291–296. [Google Scholar]
  25. Lehtihet, M. , Arver, S. , Bartuseviciene, I., Pousette, Å., S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels. Andrologia 2012, 44, 405–410. [Google Scholar] [PubMed]
  26. Livingston, M. , Hackett, G. , Ramachandran, S., Heald, A., Is a fasting testosterone level really necessary for the determination of androgen status in men? Clinica Chimica Acta 2021, 521, 64–69. [Google Scholar]
  27. Morales, A. , Bebb, R. A., Manjoo, P., Assimakopoulos, P., et al., Diagnosis and management of testosterone deficiency syndrome in men: Clinical practice guideline. Cmaj 2015, 187, 1369–1377. [Google Scholar]
  28. Bhasin, S. , Cunningham, G. R., Hayes, F.J., Matsumoto, A.M., et al., Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 2010, 95, 2536–2559. [Google Scholar]
  29. Gibney, J. , Smith, T. , McKenna, T., The impact on clinical practice of routine screening for macroprolactin. The Journal of Clinical Endocrinology & Metabolism 2005, 90, 3927–3932. [Google Scholar]
  30. Heald, A. , Blantern, E., Anderson, S., Radford, D., et al., Quantitative adjustment for macroprolactin is an integral part of laboratory assessment of hyperprolactinaemia. Experimental and Clinical Endocrinology & Diabetes 2012, 376–380.
  31. Grossmann, M. , Towards optimising diagnosis and management of male hypogonadism: Commentary on CEN-2023-000285 “standardising the biochemical confirmation of adult male hypogonadism” a joint position statement by the society for endocrinology and association of clinical biochemistry and laboratory medicine”. Clinical Endocrinology 2023.
  32. Ramachandran, S. , König, C. S., Hackett, G., Livingston, M., et al., Managing clinical heterogeneity: An argument for benefit-based action limits. Journal of Engineering and Science in Medical Diagnostics and Therapy 2018, 1, 034701. [Google Scholar]
  33. Jayasena, C.N., Silva, N.L. de, OReilly, M.W., MacKenzie, F., et al., Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the society for endocrinology and association of clinical biochemistry and laboratory medicine. Clinical Endocrinology 2023.
  34. Stanworth, R. , Kapoor, D. , Channer, K., Jones, T., Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology 2008, 159, 739–746. [Google Scholar] [PubMed]
  35. Tirabassi, G., Cignarelli, A., Perrini, S., Furlani, G., et al., Influence of CAG repeat polymorphism on the targets of testosterone action. International Journal of Endocrinology 2015, 2015.
  36. Heald, A. , Cook, M. , Antonio, L., Vanderschueren, D., et al., The number of androgen receptor CAG repeats and mortality in men. The Aging Male 2022, 25, 167–172. [Google Scholar]
  37. Heald, A.H. , Livingston, M. , Fachim, H., Lunt, M., et al., Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: A prospective cohort study. Cardiovascular Endocrinology & Metabolism 2021, 10, 37. [Google Scholar]
  38. Snyder, P.J. , Bhasin, S. , Cunningham, G.R., Matsumoto, A.M., et al., Effects of testosterone treatment in older men. New England Journal of Medicine 2016, 374, 611–624. [Google Scholar]
  39. Shores, M.M. , Smith, N. L., Forsberg, C.W., Anawalt, B.D., et al., Testosterone treatment and mortality in men with low testosterone levels. The Journal of Clinical Endocrinology & Metabolism 2012, 97, 2050–2058. [Google Scholar]
  40. Muraleedharan, V. , Marsh, H. , Kapoor, D., Channer, K.S., et al., Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology 2013, 169, 725–733. [Google Scholar]
  41. Hackett, G. , Cole, N. , Mulay, A., Strange, R.C., et al., Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. BJU International 2019, 123, 519–529. [Google Scholar]
  42. Hackett, G. , Heald, A. , Sinclair, A., Jones, P., et al., Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: Retrospective consideration of the impact of PDE5 inhibitors and statins. International Journal of Clinical Practice 2016, 70, 244–253. [Google Scholar]
  43. Greco, E.A. , Spera, G. , Aversa, A., Combining testosterone and PDE5 inhibitors in erectile dysfunction: Basic rationale and clinical evidences. European Urology 2006, 50, 940–947. [Google Scholar]
  44. Kapoor, D. , Goodwin, E. , Channer, K., Jones, T., Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006, 154, 899–906. [Google Scholar] [PubMed]
  45. Malkin, C.J. , Pugh, P. J., West, J.N., Beek, E.J. van, et al., Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. European Heart Journal 2006, 27, 57–64. [Google Scholar]
  46. Tajar, A. , McBeth, J. , Lee, D.M., Macfarlane, G.J., et al., Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older european men. PAIN 2011, 152, 1495–1501. [Google Scholar]
  47. Heald, A.H. , Stedman, M. , Whyte, M., Livingston, M., et al., Lessons learnt from the variation across 6741 family/general practices in england in the use of treatments for hypogonadism. Clinical Endocrinology 2021, 94, 827–836. [Google Scholar]
  48. Testa, M.A. , Simonson, D. C., Assessment of quality-of-life outcomes. New England Journal of Medicine 1996, 334, 835–840. [Google Scholar] [CrossRef]
  49. Amanatkar, H.R. , Chibnall, J. T., Seo, B.-W., Manepalli, J.N., et al., Impact of exogenous testosterone on mood: A systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry 2014, 26, 19–32. [Google Scholar]
  50. Wu, F. , Zitzmann, M. , Heiselman, D., Donatucci, C., et al., Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2%. The Journal of Sexual Medicine 2016, 13, 1212–1219. [Google Scholar]
  51. O’Connell, M. , Tajar, A. , Roberts, S.A., Wu, F., Do androgens play any role in the physical frailty of ageing men? International Journal of Andrology 2011, 34, 195–211. [Google Scholar]
  52. Saad, F. , The relationship between testosterone deficiency and frailty in elderly men. Hormone Molecular Biology and Clinical Investigation 2010, 4, 529–538. [Google Scholar] [CrossRef]
  53. Snyder, P.J. , Kopperdahl, D. L., Stephens-Shields, A.J., Ellenberg, S.S., et al., Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. JAMA Internal Medicine 2017, 177, 471–479. [Google Scholar]
  54. Saad, F. , Aversa, A. , Isidori, A.M., Zafalon, L., et al., Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology 2011, 165, 675–685. [Google Scholar]
  55. Barbonetti, A. , D’Andrea, S. , Francavilla, S., Testosterone replacement therapy. Andrology 2020, 8, 1551–1566. [Google Scholar] [PubMed]
  56. Jayasena, C.N. , Anderson, R. A., Llahana, S., Barth, J.H., et al., Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clinical Endocrinology 2022, 96, 200–219. [Google Scholar]
  57. Jones, T.H. , Arver, S. , Behre, H.M., Buvat, J., et al., Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34, 828–837. [Google Scholar]
  58. Hackett, G. , Heald, A. , Sinclair, A., Jones, P., et al., Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: Retrospective consideration of the impact of PDE5 inhibitors and statins. International Journal of Clinical Practice 2016, 70, 244–253. [Google Scholar]
  59. Wittert, G. , Bracken, K. , Robledo, K.P., Grossmann, M., et al., Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): A randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. The Lancet Diabetes & Endocrinology 2021, 9, 32–45. [Google Scholar]
  60. Vigen, R. , O’Donnell, C. I., Barón, A.E., Grunwald, G.K., et al., Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. Jama 2013, 310, 1829–1836. [Google Scholar]
  61. Finkle, W.D. , Greenland, S. , Ridgeway, G.K., Adams, J.L., et al., Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS One 2014, 9, e85805. [Google Scholar]
  62. Lincoff, A.M., Bhasin, S., Flevaris, P., Mitchell, L.M., et al., Cardiovascular safety of testosteronereplacement therapy. New England Journal of Medicine 2023.
  63. Jayasena, C.N. , Silva, N. L. de, O’Reilly, M.W., MacKenzie, F., et al., Standardising the biochemical confirmation of adult male hypogonadism$\mathsemicolon$ a joint position statement by the society for endocrinology and association of clinical biochemistry and laboratory medicine. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 2023, 60, 223–227. [Google Scholar]
  64. Cao, Z.T. , Botelho, J. C., Rej, R., Vesper, H., et al., Impact of testosterone assay standardization efforts assessed via accuracy-based proficiency testing. Clinical Biochemistry 2019, 68, 37–43. [Google Scholar]
  65. Travison, T.G. , Vesper, H. W., Orwoll, E., Wu, F., et al., Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the united states and europe. The Journal of Clinical Endocrinology & Metabolism 2017, 102, 1161–1173. [Google Scholar]
Table 1. Symptoms and signs of male hypogonadism.
Table 1. Symptoms and signs of male hypogonadism.
Symptoms/signs Details
Low libido Reduced interest in sex or sexual desires
Erectile dysfunction Difficulty in achieving/maintaining penile erections
Fatigue Persistent tiredness, lack of energy, reduced stamina
Reduced muscle mass Reduced muscular strength and size
Increased body fat Weight gain, especially around the abdomen
Hair Loss Loss or thinning of facial and body hair
Gynecomastia Enlargement of breast tissue in men
Infertility Due to reduced sperm production
Osteoporosis Decreased bone mineral density, increased risk of fractures
Mood/mental changes Mood swings, irritability, depression, reduced cognition
Hot flushes Sudden intense feelings of heat, akin to those experienced in female menopause
Testicle size May become smaller than usual
Metabolic changes Type 2 diabetes, metabolic syndrome, dyslipidaemia
Table 2. Causes of male hypogonadism.
Table 2. Causes of male hypogonadism.
Primary hypogonadism
Congenital anorchidism
Cryptorchidism
Mumps orchitis
Genetic and developmental conditions: Klinefelter syndrome, androgen receptor and enzyme defects
Sertoli cell only syndrome
Radiation treatment ⁄chemotherapy
Testicular trauma
Autoimmune syndromes (anti-Leydig cell disorders)
Secondary hypogonadism
Genetic conditions: Kallmann’s syndrome, Prader-Willi syndrome
Pituitary tumour, granuloma, abscess, infiltration (e.g., sarcoidosis)
Hyperprolactinemia
Cranial trauma
Radiation treatment
Various medications
Mixed (primary and secondary) hypogonadism
Alcohol abuse
Ageing
Chronic infections (HIV)
Corticosteroid treatment
Haemochromatosis
Systemic disorders: liver failure, uraemia, sickle-cell disease
Table 3. Factors affecting serum testosterone (T) levels in adult males.
Table 3. Factors affecting serum testosterone (T) levels in adult males.
Factor Details
Age T levels decrease with age, gradually declining with each decade after age of 30–40 years
Testicular dysfunction Any condition or injury affecting the testes can lead to decreased T secretion
Genetics Genetic factors play a role in determining an individual’s baseline T levels and their sensitivity to hormonal changes
Obesity Serum total T levels are reported to be lower in obese men (body mass index >30 kg/m2)
Diurnal variation Levels are highest in the morning (around 09:00AM) and up to 60% lower in the evening
Seasonal variations T levels may fluctuate slightly throughout the year, with peaks in the summer–early autumn and troughs in the winter–early spring, but published studies are contradictory
Acute illness/infection Acute illnesses or infections can temporarily cause reductions in T concentrations (as T is a negative acute phase reactant)
Chronic illness Chronic conditions (e.g., diabetes, liver disease, kidney disease) can influence T production
Stress Ongoing stress can affect hormone regulation, potentially causing lower T levels
Sleep Inadequate or disrupted sleep can affect T production
Fasting status Up to 30% increase is reported in fasting subjects
Physical activity Regular exercise/physical activity can positively influence T levels
Medication
Alcohol/drug abuse
Binding proteins		 Some medications (e.g., corticosteroids, opioids) may interfere with T secretion/utilisation
Excessive alcohol consumption/drug abuse can negatively affect T levels
Concentration of relevant binding proteins (e.g., sex hormone-binding globulin)
Table 4. Factors affecting Sex Hormone Binding Globulin.
Table 4. Factors affecting Sex Hormone Binding Globulin.
Increase Decrease
Aging Obesity
Hyperthyroidism Hypothyroidism
Oestrogens Androgens
Hepatic diseases Insulin resistance
Cirrhosis Hyperinsulinism
Anti-epileptics Hyperprolactinemia
Tamoxifen Growth Hormone, acromegaly
Steroids Hypercortisolism
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated